Your account is not claimed yet. You can sign up with ORCID to claim your account.

Sean G Rudd

ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 15

Top Venues

Cell death & disease

Nature communications

Nature chemical biology

PeerJ

Karolinska Institutet

University of Sussex (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Karolinska Institutet Jan 1o 2019

Sweden

Assistant Professor :: Department of Oncology Pathology

Education History

University of Sussex

United Kingdom

PHD :: Genome Damage & Stability Centre

Publications

Sean G Rudd
Targeting pan-essential pathways in cancer with cytotoxic chemotherapy: challenges and opportunities. Cancer chemotherapy and pharmacology (2023)
Thomas Helleday, Sean G Rudd
Targeting the DNA damage response and repair in cancer through nucleotide metabolism. Molecular oncology 16 (21) (2022)
Jiantao Wang, Siyuan Hao, Junjie Gu, Sean G Rudd, Yan Wang
The prognostic and clinicopathological significance of desmoglein 2 in human cancers: a systematic review and meta-analysis. PeerJ 10 (2022)
Sophia Ceder, Sofi E Eriksson, Ying Yu Liang, Emarndeena H Cheteh, Si Min Zhang, Kenji M Fujihara, Julie Bianchi, Vladimir J N Bykov, Lars Abrahmsen, Nicholas James Clemons, Pär Nordlund, Sean G Rudd, Klas G Wiman
Correction: Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells. Cell death & disease 13 (8) (2022)
Sophia Ceder, Sofi E Eriksson, Ying Yu Liang, Emarndeena H Cheteh, Si Min Zhang, Kenji M Fujihara, Julie Bianchi, Vladimir J N Bykov, Lars Abrahmsen, Nicholas James Clemons, Pär Nordlund, Sean G Rudd, Klas G Wiman
Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells. Cell death & disease 12 (7) (2021)
Petri Mäkelä, Si Min Zhang, Sean G Rudd
Drug synergy scoring using minimal dose response matrices. BMC research notes 14 (1) (2021)
Si Min Zhang, Matthieu Desroses, Anna Hagenkort, Nicholas C K Valerie, Daniel Rehling, Megan Carter, Olov Wallner, Tobias Koolmeister, Adam Throup, Ann-Sofie Jemth, Ingrid Almlöf, Olga Loseva, Thomas Lundbäck, Hanna Axelsson, Shruti Regmi, Antonio Sarno, Andreas Krämer, Linda Pudelko, Lars Bräutigam, Azita Rasti, Mona Göttmann, Elisée Wiita, Juliane Kutzner, Torsten Schaller, Christina Kalderén, Armando Cázares-Körner, Brent D G Page, Rosa Krimpenfort, Saeed Eshtad, Mikael Altun, Sean G Rudd, Stefan Knapp, Martin Scobie, Evert J Homan, Ulrika Warpman Berglund, Pål Stenmark, Thomas Helleday
Development of a chemical probe against NUDT15. Nature chemical biology 16 (10) (2020)
Sean G Rudd, Helge Gad, Kumar Sanjiv, Nuno Amaral, Anna Hagenkort, Petra Groth, Cecilia E Ström, Oliver Mortusewicz, Ulrika Warpman Berglund, Thomas Helleday
MTH1 Inhibitor TH588 Disturbs Mitotic Progression and Induces Mitosis-Dependent Accumulation of Genomic 8-oxodG. Cancer research 80 (17) (2020)
Sean G Rudd, Nikolaos Tsesmetzis, Kumar Sanjiv, Cynthia Bj Paulin, Lakshmi Sandhow, Juliane Kutzner, Ida Hed Myrberg, Sarah S Bunten, Hanna Axelsson, Si Min Zhang, Azita Rasti, Petri Mäkelä, Si'Ana A Coggins, Sijia Tao, Sharda Suman, Rui M Branca, Georgios Mermelekas, Elisée Wiita, Sun Lee, Julian Walfridsson, Raymond F Schinazi, Baek Kim, Janne Lehtiö, Georgios Z Rassidakis, Katja Pokrovskaja Tamm, Ulrika Warpman-Berglund, Mats Heyman, Dan Grandér, Sören Lehmann, Thomas Lundbäck, Hong Qian, Jan-Inge Henter, Torsten Schaller, Thomas Helleday, Nikolas Herold
Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy. EMBO molecular medicine 12 (3) (2020)
Brent D G Page, Nicholas C K Valerie, Roni H G Wright, Olov Wallner, Rebecka Isaksson, Megan Carter, Sean G Rudd, Olga Loseva, Ann-Sofie Jemth, Ingrid Almlöf, Jofre Font-Mateu, Sabin Llona-Minguez, Pawel Baranczewski, Fredrik Jeppsson, Evert Homan, Helena Almqvist, Hanna Axelsson, Shruti Regmi, Anna-Lena Gustavsson, Thomas Lundbäck, Martin Scobie, Kia Strömberg, Pål Stenmark, Miguel Beato, Thomas Helleday
Author Correction: Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells. Nature communications 10 (1) (2019)
Nikolaos Tsesmetzis, Cynthia B J Paulin, Sean G Rudd, Nikolas Herold
Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism. Cancers 10 (7) (2018)
George Z Rassidakis, Nikolas Herold, Ida Hed Myrberg, Nikolaos Tsesmetzis, Sean G Rudd, Jan-Inge Henter, Torsten Schaller, Siok-Bian Ng, Wee Joo Chng, Benedict Yan, Chin Hin Ng, Farhad Ravandi, Michael Andreeff, Hagop M Kantarjian, L Jeffrey Medeiros, Ioanna Xagoraris, Joseph D Khoury
Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens. Blood cancer journal 8 (11) (2018)
Brent D G Page, Nicholas C K Valerie, Roni H G Wright, Olov Wallner, Rebecka Isaksson, Megan Carter, Sean G Rudd, Olga Loseva, Ann-Sofie Jemth, Ingrid Almlöf, Jofre Font-Mateu, Sabin Llona-Minguez, Pawel Baranczewski, Fredrik Jeppsson, Evert Homan, Helena Almqvist, Hanna Axelsson, Shruti Regmi, Anna-Lena Gustavsson, Thomas Lundbäck, Martin Scobie, Kia Strömberg, Pål Stenmark, Miguel Beato, Thomas Helleday
Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells. Nature communications 9 (1) (2018)
Nikolas Herold, Sean G Rudd, Kumar Sanjiv, Juliane Kutzner, Julia Bladh, Cynthia B J Paulin, Thomas Helleday, Jan-Inge Henter, Torsten Schaller
SAMHD1 protects cancer cells from various nucleoside-based antimetabolites. Cell cycle (Georgetown, Tex.) 16 (11) (2017)
Sean G Rudd, Torsten Schaller, Nikolas Herold
SAMHD1 is a barrier to antimetabolite-based cancer therapies. Molecular & cellular oncology 4 (2) (2017)

Sean G Rudd.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Sean G Rudd